These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 12414537

  • 1. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
    Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB.
    Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
    [Abstract] [Full Text] [Related]

  • 2. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
    Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6966-71. PubMed ID: 16203789
    [Abstract] [Full Text] [Related]

  • 3. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
    Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB.
    Clin Cancer Res; 2002 Oct 01; 8(10):3226-31. PubMed ID: 12374693
    [Abstract] [Full Text] [Related]

  • 4. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.
    Mesiano S, Ferrara N, Jaffe RB.
    Am J Pathol; 1998 Oct 01; 153(4):1249-56. PubMed ID: 9777956
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
    Yukita A, Asano M, Okamoto T, Mizutani S, Suzuki H.
    Anticancer Res; 2000 Oct 01; 20(1A):155-60. PubMed ID: 10769648
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB.
    Cancer Res; 2002 Feb 15; 62(4):1087-92. PubMed ID: 11861387
    [Abstract] [Full Text] [Related]

  • 11. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, Kadenhe A, New T, Yokoi A, Yamashiro DJ, Kandel JJ, Middlesworth W.
    J Pediatr Surg; 2003 Mar 15; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [Abstract] [Full Text] [Related]

  • 12. Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice.
    Choi EK, Kim SW, Nam EJ, Paek J, Yim GW, Kang MH, Kim YT.
    Reprod Sci; 2011 Aug 15; 18(8):763-71. PubMed ID: 21421899
    [Abstract] [Full Text] [Related]

  • 13. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
    Gossmann A, Helbich TH, Mesiano S, Shames DM, Wendland MF, Roberts TP, Ferrara N, Jaffe RB, Brasch RC.
    Am J Obstet Gynecol; 2000 Oct 15; 183(4):956-63. PubMed ID: 11035346
    [Abstract] [Full Text] [Related]

  • 14. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
    Borgström P, Gold DP, Hillan KJ, Ferrara N.
    Anticancer Res; 1999 Oct 15; 19(5B):4203-14. PubMed ID: 10628376
    [Abstract] [Full Text] [Related]

  • 15. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
    Dagnaes-Hansen F, Rasmussen LM, Tilton R, Denner L, Flyvbjerg A.
    Anticancer Res; 2003 Oct 15; 23(2B):1625-30. PubMed ID: 12820432
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
    Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R.
    Cancer Res; 2003 Sep 01; 63(17):5224-9. PubMed ID: 14500349
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.